HIGHLIGHTS
- who: You-Cheng Li and colleagues from the Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University have published the paper: Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia, in the Journal: (JOURNAL)
- what: Significant comorbidities or a high probability of induction failure may be the primary reasons for ineligibility for remission induction chemotherapy. This study was approved by the Review Board of Taichung Veterans General Hospital (CE21114A) and was conducted in accordance with the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.